

Transforming cancer care with the first **FDA cleared** medical device for the capture and harvest of circulating tumour cells



Interim Results for the six months ended 30 June 2025

Andrew Newland and Ian Griffiths
9 September 2025



This presentation has been prepared by ANGLE plc (the "Company"). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions.

The presentation slides which follow this notice and the oral presentation of which it forms part (together, the "Materials") are personal to the recipient and have been prepared and issued by or on behalf of the Company. For the purposes of the remainder of this notice, the term Materials shall include the presentation, the question-and-answer session that follows the presentation, hard or electronic copies of this document and any other materials distributed at, or in connection with, the presentation. The recipient agrees to return all Materials held by it in relation to this presentation upon the Company's request.

The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this presentation and any errors therein or omissions therefrom.

This presentation does not constitute or form any part of, and should not be construed as, an offer to sell, or an invitation or solicitation or recommendation to purchase, or subscribe for or underwrite or otherwise acquire any securities in the Company in any jurisdiction and does not constitute or form part of a prospectus. No part of this presentation should form the basis of, or be relied on in connection with, or act as any inducement to enter into, any contract or commitment or investment decision whatsoever. The Company's nominated adviser, Joh. Berenberg, Gossler & Co. KG (London branch) ("Berenberg") has not approved this document for the purposes of section 21 of the Financial Services and Markets Act 2000 ("FSMA") and accordingly it is a communication directed only at persons whose ordinary activities involve them acquiring, holding, managing and disposing of investments (as principal or agent) for the purposes of their business and who have professional experience in matters relating to investments and are (1) if in a member state of the European Economic Area ("EEA"), "Qualified Investors" as defined in Article 2(E) of Regulation (EU) 2017/1129 (the "EU Prospectus Regulation") ("EU Qualified Investors"), (2) if in the United Kingdom, "Qualified Investors" as defined in Article 2(E) of the EU Prospectus Regulation, which forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation") who (a) fall within one or more of the exemptions from section 21 of FSMA contained in the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts) ("UK Qualified Investors") or (3) persons to whom it may otherwise be lawful to communicate it (all such persons together being referred as "Relevant Persons"). Any investment or investment activity to which this document relates is only available to the Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to Berenberg or the Company immediately.

This presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under FSMA).

This presentation contains certain statements that are neither reported financial results nor other historical information. These statements include information with respect to the Company's financial condition, its results of operations and businesses, strategy, plans and objectives. Words such as "anticipates", "expects", "should", "intends", "plans", "believes", "outlook", "seeks", "estimates", "targets", "may", "will", "continue", "project" and similar expressions, as well as statements in the future tense, identify forward-looking statements. These forward-looking statements are not guarantees of the Company's future performance and are subject to assumptions, risks and uncertainties that could cause actual future results to differ materially from those expressed in or implied by such forward-looking statements. No statement in the Materials is intended to be nor may it be construed as a profit forecast. Many of these assumptions, risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely and include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Company's and its subsidiaries' (the "Group") research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group's products by customers.

For further details regarding these and other assumptions, risks and uncertainties that may affect the Group, please read the Directors' Report section including the "Principal Risks and Uncertainties" in the most recent Annual Report & Financial Statements of the Company. In addition, new factors emerge from time to time and the Company cannot assess the potential impact of any such factor on its activities or the extent to which any factor, or combination of factors, may cause actual future results to differ materially from those contained in any forward-looking statement. Except as may be required by law or regulation, the Company undertakes no obligation to update any of its forward-looking statements, which speak only as of the date of this document.

First Half Highlights



Half year

- **Three large Pharma contracts completed successfully** with discussions for additional work ongoing
 - Eisai: HER2 breast cancer
 - AstraZeneca: DDR multiple cancers
 - AstraZeneca: AR prostate cancer
- **DNA Dual Analysis Illumina NGS assay**
- Research published in Nature Medicine highlighting potential for **cluster-buster drugs** enabled by Parsortix

Post period end

- **First large medtech company collaboration signed with Myriad Genetics**
- Pipeline of opportunities with multiple large medtech and large pharma companies
- **Discussions progressing with the UK NHS**
- **Clinical lab accreditation** progressing well to offer clinical services

Progress across multiple fronts despite adverse market conditions

Financial Results for the six months ended 30 June 2025

	Six months ended 30 June 2025 £'000	Six months ended 30 June 2024 £'000	Year ended 31 December 2024 £'000
Statement of Comprehensive Income			
Revenue	796	1,034	2,862
Cost of sales	(330)	(423)	(1,083)
Gross profit	466	611	1,779
Operating costs - cash	(6,754)	(7,500)	(14,136)
Operating costs - non-cash*	(3,389)	(1,414)	(2,739)
Tax credit and net finance costs	409	590	871
Loss for the period	(9,268)	(7,713)	(14,225)
Other comprehensive income / (loss)**	2,107	(162)	(376)
Total comprehensive income / (loss)	(7,161)	(7,875)	(14,601)
Earnings per share (pence)	(2.87)	(2.89)	(4.82)
	30 June 2025 £'000	30 June 2024 £'000	31 December 2024 £'000

Statement of Financial Position

Trade and other receivables and R&D tax credit	3,025	3,977	4,404
Inventories	1,573	1,761	1,579
Cash and cash equivalents	5,270	17,882	10,425
Property, plant & equipment and right-of-use assets	5,585	6,703	6,402
Intangible assets	2,631	2,659	2,648
Total assets	18,084	32,982	25,458

*Share-based payments, depreciation, amortisation, unrealised FX on Group loans

** Exchange differences on translating foreign operations

Highlights

- Pharma revenue down on prior year. Product revenue flat
- Operating costs excluding non-cash forex down 12%
- Comprehensive loss for period down 7%
- Planned operating expenditure (cash) of £6.8 million, reduced by 10%
- Cash and R&D tax credits £6.6 million with cash runway into Q1 2026
- Additional funding key focus

Integrated NGS Workflow with Illumina

Dual genomic profiling from a single blood sample



illumina

Strategic Innovation


ANGLE has developed a proprietary workflow integrating its Parsortix system with Illumina's sequencing technology, enabling simultaneous genomic analysis of both CTC-DNA and ctDNA

Clinical Advantage

This dual profiling approach delivers a comprehensive molecular view of cancer, significantly enhancing mutation detection compared to ctDNA alone

Key Data Highlights (Presented at Illumina webinar and EACR congress):

- 100% mutation detection in untreated lung cancer patients via CTC-DNA
- 90% mutation detection in treated lung cancer patients via CTC-DNA
- 2x more mutations identified with dual analysis vs. ctDNA alone



Potential to drive adoption in clinical trials, companion diagnostics, and personalised medicine

Strategic Collaboration with Myriad Genetics



Partnership Overview:

Myriad Genetics (Market Cap: \$615M; 2024 Revenue: \$838M, +11% YoY) and ANGLE to investigate the integration of the Parsortix system into the existing tissue-based workflow

Clinical Impact:

CTCs will be harvested by the Parsortix system from patient blood samples. CTC-DNA will be analysed and benchmarked against matched tissue samples using Myriad's validated tissue-based assay, enabling direct comparison and validation

Value Proposition:

This collaboration positions the Parsortix system as a critical enabler of minimally invasive, repeatable molecular diagnostics, potentially expanding Myriad's testing capabilities and improving patient stratification and longitudinal monitoring

CTCs - a potential new sample type for existing tissue-based tests

- The Parsortix system provides access to **CTCs, complete, living cancer cells**, which could be analysed using assays which have historically relied on a tissue sample
- Potential to **broaden patient base** by enabling repeatable, minimally invasive, longitudinal monitoring.
- This significantly **expands the market** potential of an assay whilst concurrently enabling **large-scale commercialisation** of the Parsortix system

Targeting metastasis: A paradigm shift in cancer treatment



Why It Matters

- CTC clusters are 100x more likely to drive metastasis than single CTCs
- 90% of cancer deaths result from metastatic disease, not the primary tumour

Market Opportunity

- Development of a first-in-class drug to dissociate CTC clusters with the potential to reduce metastasis, making more cancers treatable
- Applicable to all solid tumours, addressing a multi-billion-dollar unmet need in oncology

Proof of Concept


- CTC cluster dissociation demonstrated in breast cancer patients using an FDA-cleared cardiac drug
- Mouse model data demonstrated treatment efficacy in preventing cancer progression

The Parsortix system is central to:

- Patient selection for clinical trials
- Monitoring treatment efficacy
- Enabling precision targeting of metastatic pathways

Prof. Nicola Aceto
Professor of Molecular
Oncology at ETH
Zurich

ETH zürich



CTC cluster in a breast cancer patient's blood sample


Platform supported by significant independent evidence



Publications as of 30 June 2025

>270 Parsortix systems in use

>248,000 Parsortix samples processed at 30 June 2025




Cumulative samples processed at 30 June 2025

Clinically relevant biomarkers including:

- EGFR
- BRAF
- KRAS
- PD-L1
- HER2
- TP53
- AR
- AR-V7
- PIK3CA
- DLL3
- PSMA

of publications by cancer type: top 8

- Breast 41
- Lung 30
- Prostate 19
- Melanoma 9
- Brain 6
- Pancreatic 6
- Ovarian 6
- Head and Neck 6



* High impact journals defined as those in quartile 1 and 2 by impact factor

Commercial milestones

Priority in H2 to capitalise on ongoing discussions with large pharma, large medtech and major healthcare providers

- Progress with **Myriad Genetics collaboration** porting tissue to CTCs
- New **large pharma contracts**
- New **large medtech collaborations** including for joint sales to pharma
- Partnership(s) for **DNA dual analysis**
- Partnership(s) for **protein analysis**
- **NHS** clinical studies
- **Clinical lab accredited**

ANGLE plc

10 Nugent Road
Surrey Research Park
Guildford GU2 7AF
United Kingdom

[angleplc.com](https://www.angleplc.com)